Sudden cardiac death is thought to be the second most common cause of mortality in
the growing population of adults with congenital heart disease (CHD), surpassed only
by heart failure–related deaths.
1
Sudden cardiac deaths account for up to 25% of all causes of mortality in adults
with CHD, with rates that vary widely across the broad spectrum of congenital heart
malformations. Risk stratification for sudden cardiac death in view of selecting appropriate
candidates for primary-prevention implantable cardioverter-defibrillators (ICDs) is
an evolving and imperfect science. Several professional societies have issued evidence-based
recommendations that are largely consistent and address diverse scenarios, including
systemic left ventricular systolic dysfunction in patients with biventricular physiology,
unexplained syncope, tetralogy of Fallot, and dysfunction of a univentricular heart
or systemic right ventricle.
2
,- Khairy P.
- van Hare G.F.
- Balaji S.
- et al.
PACES/HRS expert consensus statement on the recognition and management of arrhythmias
in adult congenital heart disease: developed in partnership between the Pediatric
and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS).
Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology
(ACC), the American Heart Association (AHA), the European Heart Rhythm Association
(EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for
Adult Congenital Heart Disease (ISACHD).
Can J Cardiol. 2014; 30: e1-e63
3
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Sudden cardiac death in congenital heart disease.Eur Heart J. 2022; 43: 2103-2115
- PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD).Can J Cardiol. 2014; 30: e1-e63
- Primary prevention implantable cardioverter-defibrillators in adults with congenital heart disease: recommendations from professional societies.Can J Cardiol. 2022; 38: 536-539
- Incidence and clinical predictors of early and late complications of implantable cardioverter-defibrillators in adults with congenital heart disease.Can J Cardiol. 2023; (XX:XXX-XX)
- Cause of death in adults with congenital heart disease—an analysis of the German National Register for Congenital Heart Defects.Int J Cardiol. 2016; 211: 31-36
- Usefulness of the MAGGIC score in predicting the competing risk of nonsudden death in heart failure patients receiving an implantable cardioverter-defibrillator: a sub-analysis of the OBSERVO-ICD registry.J Clin Med. 2021; 11: 121
- Sudden cardiac arrest with shockable rhythm in patients with heart failure.Heart Rhythm. 2020; 17: 1672-1678
- Changing incidence of out-of-hospital ventricular fibrillation, 1980-2000.JAMA. 2002; 288: 3008-3013
- Sudden cardiac death in adult congenital heart disease.Circulation. 2012; 126: 1944-1954
- Implantable cardioverter-defibrillators and patient-reported outcomes in adults with congenital heart disease: an international study.Heart Rhythm. 2020; 17: 768-776
- Shock-related anxiety and sexual function in adults with congenital heart disease and implantable cardioverter defibrillators.Heart Rhythm. 2013; 10: 805-810
- Incorporating utility-based quality-of-life assessment measures in clinical trials. Two examples.Med Care. 1989; 27: S190-S204
- QALYs in cost-effectiveness analysis: an overview for cardiologists.Heart. 2015; 101: 1868-1873
- The utility of different health states as perceived by the general public.J Chronic Dis. 1978; 31: 697-704
Article info
Publication history
Published online: December 13, 2022
Accepted:
December 9,
2022
Received:
December 2,
2022
Publication stage
In Press Journal Pre-ProofFootnotes
See article by Albertini et al., pages XXX-XX of this issue.
Identification
Copyright
© 2022 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Incidence and Clinical Predictors of Early and Late Complications of Implantable Cardioverter-Defibrillators in Adults With Congenital Heart DiseaseCanadian Journal of Cardiology
- PreviewThe implantable cardioverter-defibrillator (ICD) has been proven to improve survival in adults with congenital heart disease (ACHD), but it is associated with a high rate of complications. We aimed to quantify the incidence of early (≤ 3 months; ECs) and late (> 3 months; LCs) complications in ACHD patients implanted with an ICD and to identify their clinical predictors.
- Full-Text
- Preview
- Development of Atrial Fibrillation in Recipients of Cardiac Resynchronization Therapy: The Role of Atrial Reverse RemodellingCanadian Journal of CardiologyVol. 28Issue 2
- PreviewWe congratulate Wilton et al. for their interesting report in a recent issue of the Canadian Journal of Cardiology, regarding the role of rate-controlled persistent atrial fibrillation (AF) on the clinical outcome and ventricular remodelling in patients receiving cardiac resynchronization therapy (CRT).1
- Full-Text
- Preview
